Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Neurodegenerative diseases - 12/12/2022 Darstellung mehrerer Neuronen mit langen Zellfortsätzen, zwischen denen sich kugelförmige Beta-Amyloid-Aggregate befinden. Die  Zellkörper sind von pTau-Fibrillen durchzogen.

    Blood-based biomarkers allow the early prediction of Alzheimer's risks

    Most dementia diseases develop insidiously and are only detected at an advanced stage. Researchers at the University of Heidelberg and the German Cancer Research Center (DKFZ) have now identified the glial fibre acidic protein (GFAP) in the blood as a promising biomarker that can be used to determine an increased risk of developing Alzheimer's disease up to 17 years before diagnosis.

    https://www.gesundheitsindustrie-bw.de/en/article/news/blood-based-biomarkers-allow-early-prediction-alzheimers-risks
  • Press release - 17/11/2022

    New target for Alzheimer's therapies found

    DZNE researchers discover link between the protein medin and Alzheimer's disease. The protein medin is deposited in the blood vessels of the brains of Alzheimer's patients along with the protein amyloid-β. DZNE Researchers have discovered this so-called co-aggregation. They have now published their observation in the renowned journal Nature.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-target-alzheimers-therapies-found
  • Press release - 20/06/2022

    Protein changes in the liquor indicate inflammatory processes in the brain

    Alzheimer's, Parkinson's and other neurodegenerative diseases are associated with inflammatory processes in the brain. German researchers have succeeded in identifying a group of proteins in the liquor that could provide information about such inflammatory processes. As so-called biomarkers, the proteins could help to better understand disease processes in the future and to test the effect of potential drugs against brain inflammation.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/protein-changes-liquor-indicate-inflammatory-processes-brain
  • Press release - 03/03/2022

    Identifying Alzheimer's risks – as early as 17 years before diagnosis

    In order to develop approaches for the prevention and treatment of Alzheimer's dementia in clinical trials, it would be helpful to be able to identify people with a particularly high risk of developing the disease. But which biomarkers can indicate an increased likelihood of disease early on in symptom-free people who actually develop Alzheimer's later?

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/identifying-alzheimers-risks-early-17-years-diagnosis
  • Neurodegenerative diseases - 30/09/2021 A computer screen with MRI images of the head, in front of which is a doctor's hand showing her patient the values on a tablet.

    Artificial intelligence enables early diagnosis of dementia

    We are all afraid of neurodegenerative diseases such as Alzheimer's and Parkinson's disease. Yet, therapies are increasingly becoming available. Although they do not cure what causes a disease, they can at least slow down its progression, provided it is diagnosed as early as possible. The Tübingen-based start-up AIRAmed has developed software that uses artificial intelligence to measure and detect changes in the brain long before they…

    https://www.gesundheitsindustrie-bw.de/en/article/news/artificial-intelligence-enables-early-diagnosis-dementia
  • Press release - 10/06/2021

    Nose2Brain – Active substances without detour through the nose into the brain

    Effective drugs for the treatment of diseases of the central nervous system do exist. However, the blood-brain barrier, which protects the brain as the body's control center, makes it especially difficult for therapeutic biomolecules to pass through. Thus, researchers from an international consortium coordinated by the Fraunhofer IGB have spent the last four and a half years developing a novel system in the EU project "N2B-patch"…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/nose2brain-active-substances-without-detour-through-nose-brain
  • Press release - 20/05/2021

    Immune cells promote proinflammatory fatty liver disease

    A particular type of dendritic cell is responsible for the tissue damage that occurs in non-alcoholic steatohepatits (NASH) in mice and humans. The dendritic cells cause aggressive, proinflammatory behavior in T cells, as now discovered by researchers from the German Cancer Research Center (DKFZ) in collaboration with colleagues from Israeli research institutes. Blocking these dendritic cells alleviates symptoms in mice.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/immune-cells-promote-proinflammatory-fatty-liver-disease
  • Press release - 17/11/2020

    The Long Road to Dementia

    The chain reaction which leads to toxic protein deposits in Alzheimer’s disease starts even earlier than assumed. Researchers from Tübingen show how this process could be stopped early on.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/long-road-dementia
  • Expert interview - 08/08/2018 Das Bild zeigt das Brustbild des ALS-Forschers, und Ärztlichen Direktors der Neurologischen Klinik der Uni Ulm, Prof. Albert Ludolph. Der Neurologe ist Sprecher des DZNE-Standorts Ulm.

    Ludolph: diagnosing and treating neurodegenerative disorders

    Ulm has long been a world leader in diagnosing and treating rare neurological disorders, notably amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and Huntington's disease (HD). We spoke with Professor Albert C. Ludolph, spokesperson for the Ulm DZNE site, medical director of the Clinic for Neurology at the RKU (University and Rehabilitation Clinics of Ulm) and world-renowned ALS researcher.

    https://www.gesundheitsindustrie-bw.de/en/article/news/ludolph-diagnosing-and-treating-neurodegenerative-disorders
  • Article - 01/02/2018 The photo shows the dentate gyrus of a rat (part of the hippocampus). The nuclei of the nerve cells that run like a ribbon from the left-hand to the right-hand side of the photo, are stained red; immature, newly formed nerve cells are white.

    Combined test systems to advance the development of drugs for treating Alzheimer’s

    Which substances are suitable for treating neurodegenerative diseases such as Alzheimer's? Due to complex biochemical relationships, testing suitable drug candidates is difficult, especially in the early drug development phase. Many predictive test systems only cover individual aspects. A team from Baden-Württemberg and France is now combining different models to develop a new approach.

    https://www.gesundheitsindustrie-bw.de/en/article/news/combined-test-systems-to-advance-the-development-of-drugs-for-treating-alzheimers
  • Press release - 05/09/2017 PET-Gerat-Uni-Tubingen.jpg

    Cell marking opens up a window into the body

    A new and particularly reliable method for marking cells can simplify research into diseases such as myocardial infarction, diabetes or Alzheimer's and reduce the use of test animals: Scientists from the University of Tübingen have developed a method by which they can target specific cell types in mice and monitor their behavior using positron emission tomography (PET). PET-based cell tracking allows scientists to observe complex life…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/cell-marking-opens-up-a-window-into-the-body
  • Article - 08/08/2017 Group of scientists in the hallway of the institute.

    N2B-patch: circumventing the blood-brain barrier

    There are many medications for treating central nervous system diseases. However, only a fraction of the active pharmaceutical ingredients actually reaches the site where they are needed. The reason for this is the blood-brain barrier that protects the brain and thus prevents many drugs used to treat neurological diseases from effectively penetrating the brain. Researchers from the Fraunhofer Institute for Interfacial Engineering and…

    https://www.gesundheitsindustrie-bw.de/en/article/news/n2b-patch-circumventing-the-blood-brain-barrier
  • Article - 26/04/2017 Schematic representation of a mechanism leading to the fragmentation of amyloid fibrils.

    Chaperones disassemble Parkinson’s disease-specific amyloid fibrils

    Amyloid fibrils consisting of clumped α-synuclein protein are characteristic of Parkinson's disease. Chaperones, which ensure the correct folding of newly synthesised polypeptides, can inhibit α-synuclein aggregation and, as a consequence, prevent fibrils from forming. Researchers from Heidelberg have shown that a specific combination of human molecular chaperones is able to disassemble fibrils and transform them into non-toxic α-synuclein…

    https://www.gesundheitsindustrie-bw.de/en/article/news/chaperones-disassemble-parkinsons-disease-specific-amyloid-fibrils
  • Article - 27/06/2016 Bading_Hilmar.jpg

    A nasal spray for treating neurodegenerative diseases

    Neuroscientists from Heidelberg have created the scientific foundations for a nasal spray that can stabilise the dendrites of nerve cells, thus reducing nerve damage and brain function losses following a stroke. Prof. Dr. Hilmar Bading and his team received the 2016 German BioRegions Innovation Prize for their invention and have set up a company called FundaMental Pharma to further accelerate the development of a marketable medicinal product.

    https://www.gesundheitsindustrie-bw.de/en/article/news/a-nasal-spray-for-treating-neurodegenerative-diseases
  • Article - 28/01/2016 BioMedX_Team_0758.jpg

    Crowdsourcing initiative to tackle Alzheimer’s

    The BioMed X Innovation Center and the biopharmaceutical company AbbVie Deutschland GmbH & Co. KG have used crowdsourcing to set up a team of scientists from renowned international institutions to investigate new options for treating Alzheimer’s disease. The team are looking for targets in the metabolism of tau proteins and its pathological modifications that can be used to develop drugs to treat Alzheimer’s disease.

    https://www.gesundheitsindustrie-bw.de/en/article/news/crowdsourcing-initiative-to-tackle-alzheimers
  • Article - 07/12/2015 Fluorescence image where plaques are clearly visible.

    Microglial cells – the health police of Alzheimer’s

    It starts with memory loss and disorientation. Alzheimer’s disease is the most common type of dementia and is characterised by the loss of neurons and synapses in the brain resulting from the aggregation of beta amyloid protein fragments into fibrils and plaques. Prof. Dr. Knut Biber and his team from the Division of Molecular Psychiatry at Freiburg University Medical Center have analysed these plaques in an in vivo-like cell culture system. They…

    https://www.gesundheitsindustrie-bw.de/en/article/news/microglial-cells-the-health-police-of-alzheimers
  • Article - 19/11/2015 Brain slice of an Alzheimer’s disease mouse model. The immune cells are black, the plaques red and have a star-like shape.

    Immune cells are reprogrammed in Alzheimer’s brains

    Scientists from the Hertie Institute for Clinical Brain Research at the University of Tübingen are pursuing an innovative treatment approach for Alzheimer’s disease using immune cells to eliminate the protein deposits that are the hallmark of Alzheimer’s. Dr. Jonas Neher and his team tested whether exchanging brain-specific immune cells with fresh, more active cells has a positive effect on the disease.

    https://www.gesundheitsindustrie-bw.de/en/article/news/immune-cells-are-reprogrammed-in-alzheimers-brains
  • Article - 01/06/2015 Prof. Dr. Elke Deuerling and Dr. Martin Gamerdinger in the laboratory.<br /> <br />

    A protein complex that maintains order in the cell

    Researchers believe that the defective transport of proteins can be linked with diseases such as Alzheimer’s. Prof. Dr. Elke Deuerling and Dr. Martin Gamerdinger, molecular biologists from the University of Konstanz, have now discovered what is necessary to prevent erroneous protein transport.

    https://www.gesundheitsindustrie-bw.de/en/article/news/a-protein-complex-that-maintains-order-in-the-cell
  • Article - 10/11/2014 22262_de.jpg

    Alzheimer: amyloid-beta triggers mitochondrial dysfunction

    Neurons are very sensitive to disturbances and many different functions are no longer able to work efficiently when the power supply is impaired. Prof. Dr. Chris Meisinger and his team at the Institute of Biochemistry and Molecular Biology at the University of Freiburg have found that amyloid-beta peptides block important enzymes in the mitochondria resulting in mitochondrial dysfunction.

    https://www.gesundheitsindustrie-bw.de/en/article/news/alzheimer-amyloid-beta-triggers-mitochondrial-dysfunction
  • Article - 03/11/2014 Photo of Prof. Jucker browsing through a journal.

    Dementia and the prion principle

    Prions are misfolded proteins that are associated with diseases such as BSE, Creutzfeldt-Jakob disease and scrapie. What makes prions particularly dangerous is their ability to induce properly folded proteins to convert into misfolded prion forms. This principle seems to be more widespread than previously thought. Dr. Mathias Jucker from the University of Tübingen and his American colleague Lary Walker from Emory University have put forward a…

    https://www.gesundheitsindustrie-bw.de/en/article/news/dementia-and-the-prion-principle
  • Article - 07/10/2013 Hans Kestler, bioinformatician from Ulm, pointing at a scientific poster.

    Hans Kestler brings order to biological data

    Hans Kestler works on the borders between the faculties, administration and different disciplines at Ulm University. Molecular biologists and life scientists at Ulm University fight over the lively engineer who is in his late forties. They all need the assistance of the systems biologist who knows how to deal with the enormous amounts of data they produce using mathematical models and algorithms.

    https://www.gesundheitsindustrie-bw.de/en/article/news/hans-kestler-brings-order-to-biological-data
  • Article - 21/05/2013 Photo of an apple, also showing the formula of ethyl 2-methylbutyrate

    Green gold: bioactive plant foods

    Nowadays everything must be good for something must have a direct noticeable or tangible effect. The ever topical issue of nutrition is no exception. All this makes functional food a promising and inexhaustible market. Teams of scientists around the world are focussing on how unhealthy food can be made healthy. Bioactive plant foods are expected to close a gap that should not have existed in the first place.

    https://www.gesundheitsindustrie-bw.de/en/article/news/green-gold-bioactive-plant-foods
  • Article - 18/03/2013 Electron microscope image of small S100A6 aggregates that form larger fibrils.

    Protein depositions in the brain promote the development of amyotrophic lateral sclerosis (ALS)

    Being aware of ones own physical degradation as intellect and cognition remain completely intact this is what the disease amyotrophic lateral sclerosis ALS also known as Lou Gehrigs disease means to sufferers. The disease is currently not curable as far too little is known as yet about its causes. However basic research is making progress and providing increasing insights into the causes of ALS. Dr. Günter Fritz and his colleagues from the…

    https://www.gesundheitsindustrie-bw.de/en/article/news/protein-depositions-in-the-brain-promote-the-development-of-amyotrophic-lateral-sclerosis-als
  • Article - 28/01/2013 19097_de.jpg

    Dietmar Thal and the Alzheimer ABC

    The initial consensus guidelines for the postmortem diagnosis of Alzheimer’s disease were published in 1997. In the same year, Dietmar Thal started his four-year research project at the Institute of Anatomy at the University of Frankfurt under the supervision of Heiko Braak, who was then one of the leading figures in Alzheimer’s research, notably for his achievements in grading the presence and distribution of tau tangles in the brain in 1991. In…

    https://www.gesundheitsindustrie-bw.de/en/article/news/dietmar-thal-and-the-alzheimer-abc
  • Article - 24/09/2012 16918_de.jpg

    Alzheimer’s disease researchers look into nutrition: can antioxidants protect against Alzheimer's?

    Citrus fruit and carrots protect against Alzheimer’s disease, a press release recently published by the University of Ulm suggests. A closer look at the language used though reveals the statement to be rather hypothetical. However, accuracy does not seem to be a concern of articles aimed at the general public, and this is exactly how expectations and hype are created. The neurologist Christine von Arnim now faces the - not inconsiderable - task…

    https://www.gesundheitsindustrie-bw.de/en/article/news/alzheimer-s-disease-researchers-look-into-nutrition-can-antioxidants-protect-against-alzheimer-s

Page 1 / 3

sb_search.block.search_result.other.pages

  • 1
  • 2
  • 3
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2023
Website address: https://www.gesundheitsindustrie-bw.de/en/search